Ribavirin: all 452 studies that test it

Page 1 of 5. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingNCT06488300Phase 2
• ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRecruitingNCT06212336Phase 2/3
• UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHFRecruitingNCT05940545Phase 1/2
• Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General HospitalCompletedNCT06922643Phase 4Results posted
• Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
• A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19TerminatedNCT04605588Phase 2Results posted
• A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT03760666Phase 1/2Results posted
• Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV SubjectsCompletedNCT03092375Phase 3Results posted
• Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC TaiwanCompletedNCT03020095Phase 2Results posted
• Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3Results posted
• Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IICompletedNCT03020004Phase 2Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedNCT02996682Phase 3Results posted
• Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C CirrhosisCompletedNCT02994056Phase 2Results posted
• Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical StudyCompletedNCT02939989Phase 3Results posted
• Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing RegimenCompletedNCT02822794Phase 3Results posted
• Study of Oral Treatments for Hepatitis CCompletedNCT02786537Phase 4Results posted
• Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and CirrhosisCompletedNCT02781558Phase 2Results posted
• Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency VirusCompletedNCT02761629Phase 4Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV InfectionCompletedNCT02738333Phase 3Results posted
• A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)CompletedNCT02731131Phase 2Results posted
• Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) StudyTerminatedNCT02717949Phase 4Results posted
• Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 InfectionCompletedNCT02716779Phase 2Results posted
• A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C InfectionCompletedNCT02673489Phase 3Results posted
• A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)CompletedNCT02641379Phase 4Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus InfectionCompletedNCT02609659Phase 3Results posted
• 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOFTerminatedNCT02605304Phase 2Results posted
• Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani PopulationCompletedNCT02601976Phase 4Results posted
• Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedNCT02601573Phase 2Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based TherapiesTerminatedNCT02600351Phase 3Results posted
• ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated CirrhosisCompletedNCT02517528Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular CarcinomaTerminatedNCT02504099Phase 3Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02493855Phase 2Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedNCT02487030Phase 3Results posted
• A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric SubjectsCompletedNCT02486406Phase 2/3Results posted
• Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected AdultsCompletedNCT02476617Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionCompletedNCT02472886Phase 3Results posted
• Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of CirrhosisTerminatedNCT02455167Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing TherapyCompletedNCT02446717Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT02442284Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in BrazilCompletedNCT02442271Phase 3Results posted
• Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected AdultsCompletedNCT02399345Phase 3Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)CompletedNCT02358044Phase 3Results posted
• A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02356562Phase 2Results posted
• Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedNCT02340962Phase 2Results posted
• Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)CompletedNCT02332720Phase 2Results posted
• Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCompletedNCT02319031Phase 3Results posted
• Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related MalignanciesCompletedNCT02308241Not applicableResults posted
• Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 CirrhoticsCompletedNCT02304159Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedNCT02292719Phase 2Results posted
• A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)CompletedNCT02265237Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-InfectionCompletedNCT02249182Phase 2Results posted
• Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in EgyptCompletedNCT02247401Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 InfectionCompletedNCT02243293Phase 2/3Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and CirrhosisCompletedNCT02226549Phase 2Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionCompletedNCT02220998Phase 3Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02219490Phase 3Results posted
• A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) InfectionCompletedNCT02216422Phase 3Results posted
• SMV + SOF With/Without RBV for IFN-II Patients With CHCCompletedNCT02214420Phase 4Results posted
• Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseCompletedNCT02207088Phase 3Results posted
• Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionCompletedNCT02202980Phase 2Results posted
• Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV InfectionCompletedNCT02201953Phase 3Results posted
• Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral TherapyTerminatedNCT02194998Phase 2Results posted
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedNCT02175966Phase 2Results posted
• Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV InfectionCompletedNCT02175758Phase 2Results posted
• A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02167945Phase 3Results posted
• Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With CirrhosisCompletedNCT02128542Phase 4Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding DisordersCompletedNCT02120300Phase 2Results posted
• Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis CCompletedNCT02118012Phase 1/2Results posted
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)CompletedNCT02105701Phase 3Results posted
• Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)CompletedNCT02105454Phase 2Results posted
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedNCT02094443Phase 2Results posted
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infectionCompletedNCT02073656Phase 3Results posted
• A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) InfectionCompletedNCT02068222Phase 2Results posted
• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver TransplantCompletedNCT02032875Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT02023112Phase 3Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver TransplantCompletedNCT02010255Phase 2Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyCompletedNCT01987453Phase 2Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV InfectionCompletedNCT01984294Phase 2Results posted
• Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV InfectionCompletedNCT01975675Phase 3Results posted
• Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV InfectionCompletedNCT01965535Phase 2Results posted
• Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal InsufficiencyCompletedNCT01958281Phase 2Results posted
• Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)CompletedNCT01945294Phase 3Results posted
• A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 CoinfectionCompletedNCT01939197Phase 2/3Results posted
• Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver TransplantCompletedNCT01938430Phase 2Results posted
• Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)CompletedNCT01932762Phase 2Results posted
• An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or BuprenorphineCompletedNCT01911845Phase 2Results posted
• Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionCompletedNCT01909804Phase 2Results posted
• Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV InfectionCompletedNCT01896193Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedNCT01854697Phase 3Results posted
• A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys TrialsCompletedNCT01853254Phase 3Results posted
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)CompletedNCT01851330Phase 3Results posted
• Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV ParticipantsCompletedNCT01849562Phase 2Results posted
• Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) InfectionCompletedNCT01838590Phase 3Results posted
• Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis CTerminatedNCT01833845Phase 1/2Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionCompletedNCT01833533Phase 3Results posted
• Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV InfectionCompletedNCT01826981Phase 2Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant RecipientsCompletedNCT01782495Phase 2Results posted
• A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionCompletedNCT01767116Phase 3Results posted
• Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)CompletedNCT01753570Phase 3Results posted
• Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedNCT01753557Phase 3Results posted

← Ribavirin overview